<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974789</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2018-03/DPDB-01</org_study_id>
    <nct_id>NCT03974789</nct_id>
  </id_info>
  <brief_title>Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms</brief_title>
  <acronym>COSHING</acronym>
  <official_title>Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a
      simple and inexpensive technology routinely used in a medical biology laboratory. They can be
      used to define robust diagnostic thresholds for salivary cortisol for the diagnosis of
      Cushing's syndrome and pseudo-Cushing combining the three tests performed as part of the
      patient's usual management. (ie two urinary free cortisol (UFC), the dexamethasone
      suppression test, and Diurnal variation of plasma cortisol).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary cortisol measured by Roche Elecsys cortisol kit</measure>
    <time_frame>Day 1 (at screening)</time_frame>
    <description>nmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salivary cortisol measured by IDS cortisol dosing kit at screening</measure>
    <time_frame>Day 1 (at screening)</time_frame>
    <description>nmol/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salivary cortisol measured by Roche Elecsys cortisol kit</measure>
    <time_frame>Day 2 and Day 3</time_frame>
    <description>nmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary cortisol measured by IDS cortisol dosing kit</measure>
    <time_frame>Day 2 and Day 3</time_frame>
    <description>nmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary cortisol measured measured by LC-MS/MS</measure>
    <time_frame>Day 1, 2 and 3</time_frame>
    <description>nmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dexamethasone suppression test</measure>
    <time_frame>Day 4</time_frame>
    <description>µg/l and nmol/l (cut-off for diagnosis: 50nmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diurnal variation of plasma cortisol</measure>
    <time_frame>Day 3</time_frame>
    <description>Roche Elecsys cortisol kiet; µg/l and nmol/l (cut-off for diagnosis: 200nmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary free cortisol</measure>
    <time_frame>Day 3</time_frame>
    <description>Radioimmunoassay; µg/l and nmol/l</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Cushing Disease</condition>
  <arm_group>
    <arm_group_label>Suspected Cushing Disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Plasma cortisol level test</description>
    <arm_group_label>Suspected Cushing Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>24-hour Urine test</intervention_name>
    <description>Urinary free cortisol test</description>
    <arm_group_label>Suspected Cushing Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Saliva swab</intervention_name>
    <description>salivette® for salivary cortisol quantification</description>
    <arm_group_label>Suspected Cushing Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dexamethasone test</intervention_name>
    <description>Dectancyl® 2 x 0.5 mg tablets (total 1 mg)</description>
    <arm_group_label>Suspected Cushing Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population of the study is patients suspected of hypercorticism. The study's
        source population will correspond to all patients (men and women) between the ages of 18
        and 65 hospitalized in the metabolic and endocrine disorders department of CHU Nîmes for
        hypercorticism assessment in primary diagnosis or in a follow-up report.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is under consultation in the department of metabolic and endocrine
             disorders at the CHU Nimes for diagnosis or follow-up of hypercortisol assessment

          -  The patient must be a member or beneficiary of a health insurance plan

        Exclusion Criteria:

          -  The patient is pregnant, parturient or breastfeeding

          -  The patient has a cardiovascular or metabolic state against the indication of
             dexamethasone

             - Patient with DFG &lt; 30 ml/min/1.73 m2

          -  The patient has suffered urinary incontinence rendering 24-hour urinary collection
             impossible or non-interpretable

          -  The patient has a urinary catheter

          -  The patient is taking corticoids (oral, inhaled, intra-venous or cutaneous)

             .Patient exposed to interfering treatments (Itraconazole, ritonavir, megestrol
             acetate, medroxyprogesterone acetate, TSH, estrogen-progestogen pill, hormonal coil)

          -  The subject is in a period of exclusion determined by a previous study

          -  The subject opposes their participation in the study

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David de Brauwere</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David-Paul de Brauwere</last_name>
    <phone>04.66.68.68.42</phone>
    <email>david.paul.de.brauwere@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>David-Paul de Brauwere</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léonore Zagdoun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Lumbroso</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie Guedj</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Taillard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Gilly</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valéria Soma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

